Time will tell. I have been in for a decade, can wait a couple more years. But I can tell you from my clinical experience that a chemistry approach is the way to go and that Elite is onto something huge. This market will be made up of only a few companies and Elite is one of them. I know it's unfathomable.
No that is mistaken. Two years ago....I stated Elite is 2-5 years away from the real money and in essence from gathering institutional investors related to launching their ART products. I have since changed my timeframe from 2-5 to 1-3 years. And to say Elite hasn't proven anything is also mistaken. The FDA giving the green light previously for Phase III related to their Eli 216 product only confirms the recent successful pivotal BE trials on their 200 and 201 products.
The company has explained repeatedly that it will only do a RS under certain conditions. A big pharma partner is one of them. In essence, it parallels what I have stated for years......the real money comes after Elite launches its ART plural and thus institutional investors climb on board when Elite's PPS is around $4.
If the company had planned on doing a RS without a partner or having launched their ART products they would've done so already.
We all know what real news is: Either a big pharma partner and/or Elite launching their first ART product. But to raise the spectre of dilution without understanding the consequences of not voting yes with the proxy vote......that is when the company will do a RS for sure IMO.
News 
Market Data 
Discover 
